KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Other financing activities (2016 - 2025)

Historic Other financing activities for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $10.0 million.

  • Amgen's Other financing activities rose 2500.0% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$111.0 million, marking a year-over-year increase of 1259.84%. This contributed to the annual value of -$124.0 million for FY2024, which is 7222.22% down from last year.
  • Per Amgen's latest filing, its Other financing activities stood at $10.0 million for Q3 2025, which was up 2500.0% from -$92.0 million recorded in Q2 2025.
  • In the past 5 years, Amgen's Other financing activities registered a high of $26.0 million during Q4 2021, and its lowest value of -$92.0 million during Q2 2025.
  • Over the past 5 years, Amgen's median Other financing activities value was -$26.0 million (recorded in 2022), while the average stood at -$25.6 million.
  • As far as peak fluctuations go, Amgen's Other financing activities skyrocketed by 96666.67% in 2021, and later tumbled by 22142.86% in 2024.
  • Amgen's Other financing activities (Quarter) stood at $26.0 million in 2021, then crashed by 61.54% to $10.0 million in 2022, then crashed by 150.0% to -$5.0 million in 2023, then soared by 60.0% to -$2.0 million in 2024, then soared by 600.0% to $10.0 million in 2025.
  • Its Other financing activities stands at $10.0 million for Q3 2025, versus -$92.0 million for Q2 2025 and -$27.0 million for Q1 2025.